CEO and President of Gilead Sciences John Milligan is looking forward to stepping down at the end of the year. Milligan who has served as CEO for two years, and according to Gilead Lead Independent Director John Cogan, has contributed to the company for nearly 30 years, commented, “I’m looking forward to a well-deserved break and moving on.”
In 2016, Milligan replaced John Martin as CEO, who moved to the position of executive chairman. The company’s announcement also stated that Martin will step down as chairman when a new CEO is named, allowing for a “natural transitions point from his successive roles as CEO, executive chairman and chairman.”
Gilead’s announcement comes only a few months after R&D Chief Norbert Bischofberger relinquished his role at the company.
Cogan stated “on behalf of the entire board, I want to thank [Milligan] […] and commend him for operating throughout his career with the highest personal and professional integrity. Given his longstanding dedication to Gilead, it is no surprise that [Milligan] is committed to facilitating a seamless transition for all of our stakeholders, as we work to identify his successor.”
(Source: Gilead Sciences; Business Wire)
Filed Under: Drug Discovery
